Results for occlusive translation from Danish to German

note for guidance on clinical investigation of medicinal products for the treatment of peripheral arterial occlusive disease
fax (32-2) 735 08 60 e-mail: mail@libeurop.be url: http://www.libeurop.be moniteur belge/belgisch staatsblad

note for guidance on clinical investigation of medicinal products for the treatment of peripheral arterial occlusive disease:
note for guidance on clinical investigation of medicinal products for the treatment of peripheral arterial occlusive disease:

titel på dokumentet note for guidance on clinical investigation of medicinal products for the treatment of diabetes mellitus note for guidance on clinical investigation of anti- depressive agents note for guidance on clinical investigation of medicinal products for pain treatment position paper on new modified formulations of acetyl salicylic acid in the secondary prevention of cardiovascular events note for guidance on clinical investigation of medicinal products for treatment of peripheral arterial occlusive disease concept paper on the revision of the note for guidance on evaluation of new anti- bacterial medicinal product (cpmp/ ewp/ 558/ 95) and the note for guidance on the pharmacodynamic section of the summary of product characteristics for antibacterial products points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications:
titel des dokuments note for guidance on clinical investigation of medicinal products for the treatment of diabetes mellitus note for guidance on clinical investigation of anti-depressive agents note for guidance on clinical investigation of medicinal products for pain treatment position paper on new modified formulations of acetyl salicylic acid in the secondary prevention of cardiovascular events note for guidance on clinical investigation of medicinal products for treatment of peripheral arterial occlusive disease concept paper on the revision of the note for guidance on evaluation of new anti-bacterial medicinal product (cpmp/ewp/558/95) and the note for guidance on the pharmacodynamic section of the summary of product characteristics for antibacterial products points to consider on biostatistical/methodological issues arising from cpmp discussion on licensing applications: